[{"id":"b7ba30e7-e92c-4c59-8947-678e08f35152","acronym":"","url":"https://clinicaltrials.gov/study/NCT04288726","created_at":"2021-01-18T20:48:49.066Z","updated_at":"2024-07-02T16:35:16.521Z","phase":"Phase 1","brief_title":"Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas","source_id_and_acronym":"NCT04288726","lead_sponsor":"Baylor College of Medicine","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11X"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2037","study_completion_date":" 06/01/2037","last_update_posted":"2024-03-04"},{"id":"c2b7af0d-ed43-45c2-88c3-a78a532de524","acronym":"","url":"https://clinicaltrials.gov/study/NCT04952584","created_at":"2021-07-07T12:53:49.491Z","updated_at":"2024-07-02T16:35:37.787Z","phase":"Phase 1","brief_title":"Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas","source_id_and_acronym":"NCT04952584","lead_sponsor":"Baylor College of Medicine","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11X"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2023-09-07"}]